Updated:
Nightingale Health Plc
Nightingale Health Plc, founded in 2013 in Helsinki, Finland, grew out of research at the University of Oulu focused on NMR-based metabolomics.
Nightingale Health Plc
Nightingale Health Plc, founded in 2013 in Helsinki, Finland, grew out of research at the University of Oulu focused on NMR-based metabolomics. The company’s platform processes blood samples using nuclear magnetic resonance spectroscopy to quantify lipid, fatty acid, and amino acid concentrations, producing standardized risk biomarkers. Teemu Suna serves as CEO, and the firm went public on the Nasdaq First North Helsinki exchange in June 2021, raising €45 million in its IPO. The company targets three primary segments: insurance, clinical trials for pharmaceutical companies, and consumer wellness. Its risk prediction models, validated in large cohort studies such as the UK Biobank, assess likelihood of cardiometabolic and neurodegenerative diseases. Nightingale reports partnerships with insurers in Europe and Asia for underwriting and wellness programs, and has collaborated with pharmaceutical firms for patient stratification in drug development. Geographic focus spans Finland, the United Kingdom, and Japan. As of 2025, Nightingale Health employs approximately 100 people, with key operations in Helsinki and a subsidiary in Tokyo, Japan. In November 2024, the firm announced an integration with the Finnish national health data platform to offer risk screening to healthcare providers (per Nightingale Health press release, November 2024). The company does not disclose assets under management, as it is not an investment firm but a health technology company. Nightingale Health’s structural differentiator is its regulatory-approved biomarker platform that enables population-scale risk assessment from a single blood sample. This positions it as a data infrastructure provider rather than a conventional family office or fund, generating recurring revenue through licensing and test kits to enterprise clients.
General information
Firm type
other
Location
Region
Europe
Country
Finland
City
Helsinki
Corporate office
Helsinki, Finland
Sector focus
Frequently asked questions
What markets does Nightingale Health operate in?
The company is headquartered in Helsinki, Finland, with a subsidiary office in Tokyo, Japan. It has commercial partnerships with insurers and healthcare providers in Finland, the United Kingdom, Japan, and other European and Asian markets. Its risk prediction models are validated using the UK Biobank cohort, giving it access to British population health data (per the firm's disclosures).
What recent events have shaped Nightingale Health's trajectory?
In November 2024, Nightingale Health announced an integration with Finland's national health data system to provide population-level chronic disease risk screening for healthcare providers. Additionally, the company continues to expand its Asian presence, particularly in Japan, where it has aligned with insurers to offer wellness programs (per press release, November 2024).
Does Nightingale Health accept investments from external LPs?
As a public company listed on the Nasdaq First North Helsinki exchange, Nightingale Health's shares are available for purchase by any investor through brokerage accounts. It does not operate as a fund with limited partners. The firm raised €45 million in its June 2021 IPO (per public filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: